Clinical Trial Regulation and Clinical Trial Disclosure & Data Transparency Conferences
6-8 December 2016
Amba Hotel Marble Arch, London, United Kingdom

CLINICAL TRIAL REGULATION CONFERENCE

While publication of the Clinical Trial Database is delayed, the endorsement of the Clinical Trial Regulation is moving forward in other areas. The Clinical Trials Regulation Conference will focus on the differences between, the present and new requirements on managing clinical trials in the face of forthcoming changes.

This 2-day conference will provide a forum for information exchange on both conceptual and practical questions of:

• How will the new legislation change the processes and the format of the trial application?
• What are the impacts on how a clinical trial is managed after approval has been granted?
• What are the critical issues affecting sponsors and Member States as they consider changes needed to implement the regulation?
• How will the new provisions for public access to an EU Clinical Trials Database enforce disclosure of clinical trial data and information?

CLINICAL TRIAL DISCLOSURE & DATA TRANSPARENCY CONFERENCE

Transparency of clinical trial information is taking on new dimensions, resulting in trial sponsors and research organisations facing a host of new requirements in the EU and the US. This 2016 Conference leverages learnings from European and US experts as well as prior conference discussions, providing the opportunity to gain insights on how to meet new challenges.

The programme is assembled around key themes:

• Impact of the EU Clinical Trial Regulation and EMA Policy 0070 on trial disclosure business processes
• Upcoming legal requirements related to disclosure of clinical research information for medicinal products and medical devices
• Real-world experiences on implementation of the regulations, including fine-tuning and optimising processes to meet the requirements for disclosure, data sharing and data transparency

Attendees will participate in the collaborative discussions through lectures, panel discussions and interactive sessions, and will learn from case studies and experiences of experts and their peers.

PROGRAMME COMMITTEES

Nick Sykes
Senior Director, Worldwide Safety & Regulatory, Pfizer Inc., UK

Surendra Gokhale
Head of Clinical Trial Regulatory Management, F. Hoffmann-La Roche Ltd, Switzerland

Elke Stahl
Clinical Trial Unit, BfArM, Germany

Robert Paarlberg
Principal, Paarlberg & Associates LLC, US

Merete Jorgensen
Director, Global Clinical Registry, Novo Nordisk A/S, Denmark

Matthias Zerm
Sr. Expert Clinical Trial Disclosure and R&D Processes, Merz Pharmaceuticals GmbH, Germany

Gerard Lynch
Associate Director, Clinical Operations, Biogen Idec Inc., United Kingdom
IN-HOUSE
TRAINING COURSES

GET YOUR WHOLE TEAM TRAINED

Ensure your staff have the knowledge and skills to be successful in their roles.

DIA would be pleased to work with you to develop programmes that ensure your teams are aligned to current industry standards.

DIA sets the educational standard against which other training providers measure themselves, and we would welcome an opportunity to discuss your training plans today.

Why choose DIA as your education partner?
• Organisation – Non-profit, education led organisation
• Faculty - Access to the widest network of distinguished faculty
• Subjects - Training provided in all areas of product development
• Expertise – Publications, Communities, Regulatory Science, Patient Engagement
• Solutions - Blended learning solution (face to face, elearning, webinar)

How does DIA deliver excellence in educational solutions?
• Assess learning objectives
• Design learning solutions
• Develop and customise
• Deliver at a time and location of your choice (worldwide)
• Assessment and feedback
• Post training analysis – future actions

Speak to us today to see how our dedicated Tailored Onsite Training team can partner with you to help resolve your challenges

Send us your request at EMEA@DIAglobal.org or call us to discuss your needs on tel. +41 61 225 5151
HALF DAY PRE-CONFERENCE WORKSHOP
5 December 2016 | 13:00–17:30

EU Clinical Trials Regulation: Anticipating the Changes
This pre-conference short course will bring you up-to-date with current developments and preparations for the implementation of the new clinical trial regulation so far. The course will complement the knowledge and information you’ll receive within the following conference days. It is recommended to take part if you did not attend last year’s clinical trial regulation conference.

Learning objectives
• You will be up to date on current preparations for the implementation of the new clinical trial regulation
• Understand the top line implementation challenges faced by sponsors, CROs, and member states

Workshop Chair:
Sini Eskola, Director Regulatory Affairs, EFPIA

12:00 Registration
13:00 Introduction including Roadmap for EU CTR implementation
Sini Eskola, Director Regulatory Affairs, EFPIA

13:30 EU CTR: preparing the organisation for change - a Sponsor perspective
Adam Smith, Development Excellence Leader; Roche, Switzerland

14:45 Refreshment Break

15:15 EU CTR: preparing for change - a CRO perspective
John Poland, Association of Clinical Research Organizations, UK

16:00 EFPIA CTMonitor
Sini Eskola, Director Regulatory Affairs, EFPIA

16:40 Voluntary Harmonization Procedure (VHP) as a stepping stone to CT Reg: Sponsor perspective
Claire Berry, Roche, Switzerland

17:20 Wrap Up
Sini Eskola, Director Regulatory Affairs, EFPIA

17:30 End of the Workshop
Separate registration required

DAY ONE | 6 December 2016

08:30 REGISTRATION AND WELCOME COFFEE

09:00 WELCOME & INTRODUCTIONS AND KEYNOTE SPEAKER
Session Chair:
Nick Sykes, Senior Director, Worldwide Safety & Regulatory, Pfizer Inc., UK

09:30 SESSION 1
CTREG IMPLEMENTATION STATUS IN MEMBER STATES
Session Chair:
Nick Sykes, Senior Director, Worldwide Safety & Regulatory, Pfizer Inc., UK

Implementation Status in Denmark
Lene Grejs Petersen, Senior Adviser, Clinical Trials, Danish Health and Medicines Agency, Denmark

Implementation Status in Italy
Sandra Petraglia, Head of Independent Research Office, AIFA - Agenzia Italiana Del Farmaco, Italy

Implementation Status in UK
Martin O’Kane, Acting Head of Clinical Trials, Medicines and Healthcare Products Regulatory Agency, UK

11:00 Coffee Break

11:30 SESSION 2
EXPERIENCES FROM PILOTS
Session Chair:
Elke Stahl, Clinical Trial Unit, BfArM, Germany

Experience with German Pilot
Elke Stahl, Clinical Trial Unit, BfArM, Germany

Experience with Spanish Regulation for Clinical Trials- Sponsor perspective
Elena Bolanos, Senior Director of Clinical Operation, Eli Lilly and Company, Spain

Panel Discussion with Q&A

12:30 Lunch

13:45 SESSION 3
TECHNICAL ISSUES
Session Chair:
Judith Creba, Head EU Liaison and Policy, Novartis Pharma AG, Switzerland

Annex VI: Discussion of the Key Issues and How to Address Them
Sini Eskola, Director Regulatory Affairs, EFPIA, Belgium

Implementation Guidance and Delegated Acts - Awareness of and the Key Identified Issues from the Draft Guidance
Isabelle Clamou, Regulatory Affairs Director - EU Policy, Amgen Ltd, Belgium

Current Thinking on Transition from CT Directive to CT Regulation
Maja Leon-Grzymkowska, Legal Officer, European Commission

Panel discussion with Q&A
15:00 Coffee Break

15:30 SESSION 4

RISK-ADAPTED TRIALS/ LOW-INTERVENTIONAL TRIALS / OBSERVATIONAL TRIALS

Session Chair:
Surendra Gokhale, Head of Clinical Trial Regulatory Management, F. Hoffmann-La Roche Ltd, Switzerland

Overview of the Guideline on Risk-Adapted Trials and Key Issues
Camelia Mihaescu, Scientific Administrator, European Medicines Agency

Case Study on a Low-Interventional Trial under the EU Directive – Issues Encountered and how These may be Addressed/made worse by the CTReg
Anastassia Negrouk, Head of International Regulatory and Intergroup Office, EORTC, Belgium

Real World Studies: Navigating the grey Between Interventional and Observational
Emma Du Four, Head of International Regulatory Policy, AbbVie, UK

Panel discussion with Q&A

16:45 SESSION 5

SAFETY REPORTING

Session Chair:
Esteban Herrero-Martinez, Director Regulatory Policy and Intelligence, AbbVie Ltd, United Kingdom

Interactive question and answer session between industry and regulators (CTFG rep and EMA rep) to discuss recent developments, outstanding issues and current thinking on clinical trial safety reporting.

Elke Stahl, Clinical Trial Unit, BfArM, Germany
Amanda Joseph, Case Management Consultant, Eli Lilly and Company, UK
Camelia Mihaescu, Scientific Administrator, European Medicines Agency

17:45 END OF DAY ONE

DAY TWO I 7 December 2016

08:30 REGISTRATION AND WELCOME COFFEE

09:00 WELCOME & INTRODUCTIONS

Nick Sykes, Senior Director, Worldwide Safety & Regulatory, Pfizer Inc., UK
Robert Paarlberg, Principal, Paarlberg & Associates LLC, US

09:15 SESSION 6

EU PORTAL & DATABASE
Anne DeBock, Sr Regional Director, AstraZeneca, Belgium

What is the status quo and what can you expect to happen in 2017? This session will answer these questions in form of high-level presentations followed by a panel discussion that focuses on the learnings so far from user-acceptance testing.

The EU Portal and Database: What to Expect. Demo of the draft Portal
Noémi Manent, Scientific Administrator, Compliance and Inspection European Medicines Agency, UK

A Stakeholder’s Perspective of the EU Clinical Trials Portal and Database
John Poland, Regulatory Affairs Consultant for ACRO, UK

10:30 Coffee Break

11:00 SESSION 7

KEY ELEMENTS OF CT DATA TRANSPARENCY IN THE EU

Session Chair:
Matthias Zerm, Sr. Expert Clinical Trial Disclosure and R&D Processes; Merz Pharmaceuticals GmbH, Germany

Get an overview of how transparency is reflected in all regulations and policies - EU CTReg, Paediatric Regulation, Data Protection Regulation and Policy 70 – and how it all comes together.

Implementation of the Clinical Trial Disclosure provisions of the CTReg
Emma Du Four, Head of International Regulatory Policy, AbbVie, UK

Mandatory Disclosure of Clinical data in the EU
Christian Fulda, Lawyer, Jones Day, Germany

12:00 Lunch

13:10 SESSION 8

EMA POLICY 0070: FIRST EXPERIENCES AND IMPLICATIONS

Session Chair:
Merete Jorgensen, Director, Global Clinical Registry Novo Nordisk A/S, Denmark

You will hear about the rules for Policy 70, and the experiences with it so far, followed by discussions how the policy can translate into actual data availability under the CTReg

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.
Clinical Trial Regulation and Clinical Trial Disclosure & Data Transparency Conferences

EMA Perspective on Policy 0070 and 0043: First Experience of Phase 1 (Submission of Clinical reports) and Plans for Phase 2 (Submission of IPD), Similarities and Differences
Anne-Sophie Henry-Eude, Head of Access to Documents Service, European Medicines Agency

Marie Isabel Manley, Partner, Head of the Regulatory Practice Solicitor, Bristows, UK

14:00 SESSION 9
EMA POLICY 0070: CHALLENGES AND TECHNIQUES FOR SPONSORS
Merete Jorgensen, Director, Global Clinical Registry Novo Nordisk A/S, Denmark

Industry Experience with Preparing Documents for Submission
Nicole Hinton, Data Transparency / Clinical Trial Results Manager, Biogen Inc., USA
Mats Ericson, Regulatory Policy Director, Amgen, France

Technical Solutions to Ease the Process of Redaction/Anonymisation/Justification
Janice Branson, Novartis Pharma AG, Switzerland
Q&A

15:15 Coffee Break

15:45 SESSION 10
PROVISION OF RESULTS TO PATIENTS
Session Chair:
Angelika Joos, Executive Director, Global Regulatory Policy, MSD (Europe) Inc., Belgium

Overview of Industry and Regulatory Initiatives (CT Regulation, UK Health Research Authority, Harvard MRCT, TransCelerate)
Angelika Joos, Executive Director, Global Regulatory Policy, MSD (Europe) Inc., Belgium

Patient Perspective – Will the Proposals Meet Patient Needs?
Richard Stephens, Chair of the Consumer Liaison Group, UK National Cancer Research Institute, UK

Patients at the Centre of Peer Review and Reporting of Research
Trish Groves, Deputy Editor, British Medical Journal, UK
Q&A

17:00 Networking Reception

18:00 END OF DAY TWO

DAY THREE I 8 December 2016

08:00 REGISTRATION AND WELCOME COFFEE

08:30 OPENING, RECAP FROM DAY 1
Merete Jorgensen
Director, Global Clinical Registry Novo Nordisk A/S, Denmark

08:45 SESSION 11 - PART 1
STATUS AND CHANGES IN RELATION TO CURRENT DISCLOSURE REQUIREMENTS IN EU AND THE USA
Session Chair:
Merete Jorgensen, Director, Global Clinical Registry Novo Nordisk A/S, Denmark

Update of EU Country Registries/Requirements
Tom Bosch, Director, Clinical Registry, Johnson & Johnson, Netherlands

EU PASS/PAES Requirements for Disclosure
Thomas Goedecke, Principal Scientific Administrator, Surveillance and Epidemiology, European Medicines Agency

09:45 Coffee Break

10:15 SESSION 11 - PART 2
STATUS AND CHANGES IN RELATION TO CURRENT DISCLOSURE REQUIREMENTS IN EU AND THE USA
Session Chair:
Merete Jorgensen, Director, Global Clinical Registry Novo Nordisk A/S, Denmark

The Final Rule for FDAAA and ClinicalTrials.gov Requirements
Rebecca J. Williams, Assistant Director, ClinicalTrials.gov, NCBI, National Library of Medicine, NIH, US
Q&A

11:15 SESSION 12
EU: PUBLIC DISCLOSURE IN UPCOMING NEW EU MEDICAL DEVICE REGULATION (MDR) AND IN-VITRO DIAGNOSTIC MEDICAL DEVICES REGULATION (IVDR)
Session Chair:
Matthias Zerm
Sr. Expert Clinical Trial Disclosure and R&D Processes, Merz Pharmaceuticals GmbH, Germany

New Clinical Trial Disclosure Requirements for Medical Devices Trials
Erik Vollebregt, Attorney, Axon Lawyers, The Netherlands

The Practical Side of Entering Data in the New MDR Eudamed
Ronald Boumans, EMERGO, Senior Global Regulatory Consultant, The Netherlands

12:00 Lunch
13:30  SESSION 13 - PART 1

CLINICAL TRIAL DATA SHARING: STATUS AND BENCHMARKING
Session Chair: Robert Paarlberg, Principal, Paarlberg & Associates LLC, US
Good Pharma Scorecard
Jennifer E. Miller, President, Bioethics International, US
Clinical Trial Transparency and the AllTrials Campaign
Síle Lane, Director of Campaigns and Policy, Sense about Science, UK
Delivering Transparency: A Research-based Approach to Confirming industry’s Commitment
Virginia Acha, Executive Director – Research, Medical & Innovation, The Association of the British Pharmaceutical Industry, UK
Panel discussion with Q&A

14:45 Coffee Break

15:00  SESSION 13 - PART 2

CLINICAL TRIAL DATA SHARING: STATUS AND BENCHMARKING
Session Chair: Robert Paarlberg
Principal, Paarlberg & Associates LLC, US
ICMJE Policy on Clinical Trial Data Sharing: From the Horse’s Mouth
Trish Groves, Deputy Editor, British Medical Journal, UK
Data Sharing and Data Protection Regulation
Martin Dræbye Gantzhorn, Life Sciences & Healthcare Expert, Horten, Denmark
Future Framework for Data Sharing
Jennifer O'Callaghan, Clinical Data Sharing Manager, Wellcome Trust, UK

16:15  END OF THE CONFERENCE

Conference Venue
Amba Hotel Marble Arch
Bryanston Street
London
W1H 7EH
United Kingdom

Presentation Access
As a benefit of registration, presentations are available on the DIA website. Please sign in to DIA Website and choose “My Presentations” within “My account”, where you will be able to download all presentations that have been submitted by speakers.

Please note that if a presentation is not available on the website, it is because:
• The presenter has not supplied us with a presentation file
• There was no slide presentation planned by the speaker
• The speaker did not agree to share it with other participants
• You have not yet paid the registration fee

Certificate of Attendance
A Certificate of Attendance will be e-mailed to all attendees after they have filled in the online evaluation. Please note certification requires full attendance to the event. For more information please contact DIA EMEA Contact Center on EMEA@DIAglobal.org or call +41 61 225 51 51.

Evaluation
We value your feedback on the content and organisation of this conference. The link to the online evaluation will be sent to you after the conference.

Continuing Education
The Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society for Pharmaceutical Medicine (SGPM) have accredited the Clinical Trial Regulation Conference with 13 credits and the Clinical Trial Disclosure & Data Transparency Conferences with 9.5 credits each.

DIA is an authorised training organisation accredited under the number 11 99 53383 75 to the Préfet of Île-de-France.
Exhibiting Companies

<table>
<thead>
<tr>
<th>Company, Country</th>
<th>Booth N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kinapse, USA</td>
<td>1</td>
</tr>
<tr>
<td>Sylogent, USA</td>
<td>2</td>
</tr>
<tr>
<td>Synchrogenix, USA</td>
<td>4</td>
</tr>
<tr>
<td>TrialScope, USA</td>
<td>5</td>
</tr>
<tr>
<td>Xogene Services, USA</td>
<td>3</td>
</tr>
</tbody>
</table>

Exhibit Hall Floor Plan

Stay Connected

Navigate DIA Meetings from Your Smart Device with DIA’s App

The DIA Global App is designed to enhance your meeting experience and provide valuable information in one place.

With the mobile app you have the conference at your fingertips:

- Create and manage your personal agenda
- Search for speakers, attendees and exhibitors to connect and network
- Share your Conference experiences through photos, posts, and more
- Activity stream provides real-time updates
- Interaction with your social media channels

Access the Clinical Trial Regulation Conference and Clinical Trial Disclosure and Data Transparency Conference 2016:

- Sign in with the Email Address You Registered for the Conference
- Use the Reset Password link to set your password | Once logged in, Select Clinical Trial Regulation Conference/Clinical Trial Disclosure and Data Transparency Conference
- Need assistance? Please feel free to ask one of our staff.
10 Themes to Build Your EuroMeeting Experience

- Theme 1: Globalisation of Global Product Health Care Development – What are the Current Successes and Challenges?
- Theme 2: Innovation of Global Product Health Care Development – What are the Key Success Factors?
- Theme 3: Current Challenges in Clinical Research
- Theme 4: eHealth/Big Data/Master- and Reference Data Management
- Theme 5: Pharmacovigilance
- Theme 6: Regulatory Science
- Theme 7: Medical Devices and Combination Products
- Theme 8: HTA, Value and Access
- Theme 9: Information on Medicines, Medical Writing and Dossier Generation
- Theme 10: Special Populations

2,500+ PARTICIPANTS 120+ EXHIBITING COMPANIES LEARN MORE DOWNLOAD PROGRAMME

DIAmond Sessions

- Major European Regulatory Science Challenges
- Current Trends and Solutions in Global Clinical Operations
- Global Regulatory Convergence
- Clinical Development Partnering 2.0

To download the programme and to register visit DIAglobal.org/EM2017